Search Results

GEODIS has renewed its IATA CEIV Pharma accreditation in Warsaw and secured GDP certification for its Stryków Dobra contract logistics facility. This dual compliance milestone bolsters Poland’s status as a critical gateway in Europe’s pharmaceutical supply chain.

The latest EFPIA Patients W.A.I.T. Indicator report reveals that Irish patients wait an average of 801 days to access newly approved medicines, prompting calls for an overhaul of the HSE and NCPE reimbursement processes and a dedicated mechanism for rare disease orphan drugs.

Ireland's contract manufacturing exports—colloquially known as "phantom exports"—are surging once again, raising fresh questions about the decoupling of headline economic figures from the domestic life sciences economy.

The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines — a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.

An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.

The United States has formally launched a trade investigation under Section 301 into Germany’s drug reimbursement practices, citing concerns that domestic price controls unfairly burden American innovation.

A detailed global report analyzing major pharmaceutical and biotech layoffs across the US, EU, and India from 2025 to 2026, including strategic shifts by enGene, Takeda, Bayer, and BioNTech.

An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.

An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.

Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.

Enterprise Ireland has announced record total exports of €38.86 billion. With the Advanced Manufacturing and Life Sciences sector surging by 14% to €13.16 billion, we analyse what this means for Ireland's homegrown pharma ecosystem.

With the US pushing for individual drug pricing deals and Germany slashing healthcare spending, the Beneluxa Initiative represents five European nations calling for a unified, coordinated approach to protect Europe's pharmaceutical innovation and access to medicines in 2026.

An in-depth analysis of Ireland's National Life Science Innovation Strategy in 2026. We examine the structural challenges of this transition-including specialised R&D infrastructure, the acute talent shortage in cell and gene therapies (CGT), and how digital compliance tools like Priya LifePDF streamline the transition.